Yahoo Finance 
Johnson & Johnson, AbbVie, and Takeda Among Leading Companies in the Ulcerative Colitis Market | GlobalData Plc
Johnson & Johnson continues to be the market leader in the ulcerative colitis market
LONDON, July 14, 2022 (GLOBE NEWSWIRE) -- The “Ulcerative Colitis – Global Drug Forecast and Market Analysis to 2029” report offered by GlobalData covers the market forecast for the marketed and late-stage pipeline UC therapeutics. The model segments patients by severity, with mild-moderate, moderate-severe, and severe/fulminant segments.
The total drug sales in the ulcerative colitis (UC) market was estimated to be $6.3 billion in 2019 across the 8MM and is expected to increase at a CAGR of more than 5% by 2029. During the forecast period, growth within the 8MM will largely be driven by the strong uptake of the IL-23 inhibitors (Skyrizi, mirikizumab, and Tremfya) and the new oral formulation S1P receptor modulators (Zeposia and etrasimod).
To get comprehensive statistics on ulcerative colitis market sizing and forecast, download a sample report
Ulcerative Colitis Market Drivers
An increase in prevalence rates in four of the eight major markets and an increase in diagnosed prevalent cases in seven markets
The approval and launch of 10 pipeline products including one reformulation
The high treatment rates across the 8MM
The high unmet need for safe efficacious therapies
For more insights on drivers and challenges in the UC market, download a sample report
Ulcerative Colitis Market - Unmet Needs and Opportunity Assessment
Despite the availability of medical treatments for UC, there are still some unmet clinical needs in several areas, especially relating to the efficacy and safety of maintenance therapies. This is due to the fact that many UC patients experience a loss of clinical response to treatment and many therapies are immunosuppressive or carry boxed warnings. Another difficulty faced by gastroenterologists is the lack of objective biomarkers to judge which therapy would most effectively treat UC and which best suits the individual patient’s condition. Knowing which treatment to prescribe first would improve patient prognosis, as treatment response can be worse in biologic-experienced patients compared to biologic-naïve ones.
Targeting unmet needs in any disease area is a highly profitable strategy for pharmaceutical companies. Most of the unmet needs in UC lie within the clinical rather than the environmental aspects of disease management, as both physician and patient awareness of UC is increasing with the help of social media and relevant charities, such as Crohn’s and Colitis UK.
For more insights into unmet needs and opportunities in the ulcerative colitis market, download a sample report
Ulcerative Colitis Market - Pipeline Assessment
GlobalData has identified nine late-stage pipeline candidates in clinical development for UC. Of the innovative targets, all are immunomodulatory/anti-inflammatory, and several aim to provide mucosal healing and offer an improvement in the maintenance of disease remission over the existing therapies. These agents include biologics and small molecules that target both inflammatory cytokines and their signaling pathways, such as interleukin inhibitors, integrin and adhesion blockers, S1P receptor modulators, and JAK inhibitors.
For more insights on the UC drugs pipeline and forecast, download a sample report
Ulcerative Colitis Market – Competitive Landscape
J&J has been the market leader in the UC space since the 2006 approval of Remicade, a mAb that works by inhibiting TNF. Remicade is considered to be the first choice of treatment among all anti-TNF agents currently available for UC due to its superior efficacy profile.
Leading Companies in the Ulcerative Colitis Market
Johnson & Johnson
AbbVie
Takeda
Pfizer
Eli Lilly
EA Pharma
Galapagos
Bristol-Myers Squibb
Arena Pharmaceuticals
To know more about leading companies in the UC market, download a sample report
Ulcerative Colitis Market Report Scope
Overview of UC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
Topline UC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting UC therapeutics sales in the 8MM.
Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
Analysis of the current and future market competition in the global UC therapeutics market as well as insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies, using a detailed overview of the current pipeline products and technologies to identify companies with the most robust pipelines.
Develop business strategies by understanding the trends shaping and driving the global UC therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global UC market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Track drug sales in the global UC therapeutics market from 2019-2029.
Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Related Reports
Sjogrens Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape – Click here
Nicotinamide Phosphoribosyltransferase (Visfatin or Pre B Cell Colony Enhancing Factor 1 or NAMPT or EC 2.4.2.12) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update – Click here
Endometriosis – Global Drug Forecast and Market Analysis to 2030 – Click here
Hemophilia A and B – Global Drug Forecast and Market Analysis, 2021-2030 – Click here
Chronic Myeloid Leukemia (CML): Global Drug Forecast and Market Analysis to 2030 – Click here
Ulcerative Colitis Market Overview
Market Size 2019 | $6.3 billion |
CAGR | >5% |
Forecast Period | 2020-2029 |
Leading Companies | Johnson & Johnson, AbbVie, Takeda, Pfizer, Eli Lilly, EA Pharma, Galapagos, Bristol-Myers Squibb, and Arena Pharmaceuticals |
FAQs
What was the ulcerative colitis market size in 2019?
The UC market size was valued at $6.3 billion in 2019.
What is the ulcerative colitis market growth rate?
The UC market is projected to grow at a CAGR of more than 5% during the forecast period, 2020-2029.
Which are the leading companies in the ulcerative colitis market?
Some of the leading companies in UC market are Johnson & Johnson, AbbVie, Takeda, Pfizer, Eli Lilly, EA Pharma, Galapagos, Bristol-Myers Squibb, and Arena Pharmaceuticals
Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Ulcerative Colitis: Executive Summary
2.1 Large Growth is Expected for UC Market from 2019–2029
2.2 Competition and Biosimilar Threat Defines UC Market
2.3 Pipeline Products Partially Address Unmet Needs
2.4 Opportunities for Managing Severe/Fulminant Patients Remain
2.5 Subcutaneous Biologics and Oral Therapies to Drive Growth in UC Market
2.6 What Do Physicians and Payers Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Gut Dysbiosis
4.1.2 The Significance of Diet
4.1.3 The Role of Interleukins
4.1.4 Environmental Factors
4.1.5 Epigenetics
4.1.6 Pathophysiology
4.1.7 Biomarkers/Targets of Interest
4.2 Classification or Staging Systems
4.3 Symptoms
4.4 Quality of Life
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Sources Not Used
5.4.3 Forecast Assumptions and Methods
5.4.4 Forecast Assumptions and Methods: Diagnosed Incident Cases of UC
5.4.5 Forecast Assumptions and Methods: Total and Diagnosed Prevalent Cases of UC
5.4.6 Forecast Assumptions and Methods: Diagnosed Prevalent Cases of UC by Severity
5.4.7 Forecast Assumptions and Methods: Post-operative UC Cases
5.5 Epidemiological Forecast for UC (2019–2029)
5.5.1 Diagnosed Incident Cases of UC
5.5.2 Age-Specific Diagnosed Incident Cases of UC
5.5.3 Sex-Specific Diagnosed Incident Cases of UC
5.5.4 Diagnosed Prevalent Cases of UC
5.5.5 Age-Specific Diagnosed Prevalent Cases of UC
5.5.6 Sex-Specific Diagnosed Prevalent Cases of UC
5.5.7 Diagnosed Prevalent Cases of UC by Severity for Ages Under 18 Years
5.5.8 Diagnosed Prevalent Cases of UC by Severity for Ages ≥18 Years
5.5.9 Post-Operative UC Cases Among Diagnosed Prevalent Cases of UC
5.5.10 Total Prevalent Cases of UC
5.5.11 Age-Specific Total Prevalent Cases of UC
5.5.12 Sex-Specific Total Prevalent Cases of UC
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Coronavirus Disease 2019 Impact
5.6.3 Limitations of the Analysis
5.6.4 Strengths of the Analysis
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 Treatment Overview
6.3 Treatment Guidelines and Leading Prescribed Drugs
6.3.1 Clinical Practice
6.3.2 Treat to Target Approach
6.4 US
6.5 5EU
6.6 Japan
6.7 Canada
7 Competitive Assessment
7.1 Overview
7.2 KOL and Payer Opinion on the Impact of COVID-19
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 Lack of Safe and Efficacious Treatment Alternatives
8.3 Improved Medical Management for Severe/Fulminant Patients
8.4 Biomarkers to Predict Responsiveness to Therapy and Prognosis
8.5 Standardization of Patient-Reported Outcomes
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Johnson & Johnson
10.4 AbbVie
10.5 Takeda
10.6 Pfizer
10.7 Eli Lilly
10.8 EA Pharma
10.9 Galapagos
10.10 Bristol-Myers Squibb
10.11 Arena Pharmaceuticals
11 Market Outlook
11.1 Global Markets
11.1.1 Forecast
11.1.2 Drivers and Barriers – Global Issues
11.2 US
11.2.1 Forecast
11.2.2 Key Events
11.2.3 Drivers and Barriers
11.3 5EU
11.3.1 Forecast
11.3.2 Key Events
11.3.3 Drivers and Barriers
11.4 Japan
11.4.1 Forecast
11.4.2 Key Events
11.4.3 Drivers and Barriers
11.5 Canada
11.5.1 Forecast
11.5.2 Key Events
11.5.3 Drivers and Barriers
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.3.1 Forecasting Methodology
12.3.2 Diagnosed Patients
12.3.3 Percent Drug-Treated Patients
12.3.4 Drugs Included in Each Therapeutic Class
12.3.5 Launch and Patent Expiry Dates
12.3.6 General Pricing Assumptions
12.3.7 Individual Drug Assumptions
12.3.8 Generic/Biosimilar Erosion
12.3.9 Pricing of Pipeline Agents
12.3.10 Compliance
12.4 Primary Research – KOLs and Payers Interviewed for This Report
12.4.1 KOLs
12.4.2 Payers
12.5 Primary Research – Prescriber Survey
12.6 About the Authors
12.6.1 Analyst
12.6.2 Therapy Area Director
12.6.3 Epidemiologist
12.6.4 Managing Epidemiologist
12.6.5 Global Director of Therapy Analysis and Epidemiology
12.6.6 Global Head and EVP of Healthcare Operations and Strategy
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer
About us
GlobalData is a leading provider of data, analytics, and insights on the world's largest industries. In an increasingly fast-moving, complex, and uncertain world, it has never been harder for organizations and decision makers to predict and navigate the future. This is why GlobalData's mission is to help our clients to decode the future and profit from faster, more informed decisions. As a leading information services company, thousands of clients rely on GlobalData for trusted, timely, and actionable intelligence. Our solutions are designed to provide a daily edge to professionals within corporations, financial institutions, professional services, and government agencies.
Media Contacts
GlobalData
Mark Jephcott
Head of PR EMEA
mark.jephcott@globaldata.com
cc: pr@globaldata.com
+44 (0)207 936 6400
